Evidence map›Paper›PMID 38928292›Full record

ArticleInternational journal of molecular sciences2024

Developing a Tanshinone IIA Memetic by Targeting MIOS to Regulate mTORC1 and Autophagy in Glioblastoma.

Sonia Shinhmar, Judith Schaf, Katie Lloyd Jones, Olivier E Pardo, Philip Beesley, Robin S B Williams

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sonia ShinhmarCentre for Biomedical Sciences, School of Biological Sciences, Royal Holloway University of London, Egham TW20 0EX, UK.
Judith SchafCentre for Biomedical Sciences, School of Biological Sciences, Royal Holloway University of London, Egham TW20 0EX, UK.ORCID 0000-0002-8638-7490
Katie Lloyd JonesCentre for Biomedical Sciences, School of Biological Sciences, Royal Holloway University of London, Egham TW20 0EX, UK.ORCID 0000-0002-3755-2525
Olivier E PardoDivision of Cancer, Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK.ORCID 0000-0003-2223-1435
Philip BeesleyCentre for Biomedical Sciences, School of Biological Sciences, Royal Holloway University of London, Egham TW20 0EX, UK.
Robin S B WilliamsCentre for Biomedical Sciences, School of Biological Sciences, Royal Holloway University of London, Egham TW20 0EX, UK.ORCID 0000-0002-9826-6020

Funding

BBSRC DTP studentship N/A
6 · The paper itself

Abstract

Tanshinone IIA (T2A) is a bioactive compound that provides promise in the treatment of glioblastoma multiforme (GBM), with a range of molecular mechanisms including the inhibition of the mechanistic target of rapamycin complex 1 (mTORC1) and the induction of autophagy. Recently, T2A has been demonstrated to function through sestrin 2 (SESN) to inhibit mTORC1 activity, but its possible impact on autophagy through this pathway has not been investigated. Here, the model system

Indexed as

AbietanesAutophagyDictyosteliumGlioblastomaMechanistic Target of Rapamycin Complex 1Cell Line, TumorCell ProliferationHumansNuclear ProteinsSestrinsAbietanesMechanistic Target of Rapamycin Complex 1Nuclear ProteinsSESN2 protein, humanSestrinstanshinoneautophagycancerDictyostelium discoideumdrug discoveryGATOR2glioblastomaMIOSmTORC1sestrintanshinone IIA

Identifiers

PMID38928292
PMCPMC11204349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.